Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Investor Presentation (June 2024)

45 slides from Day One Biopharmaceuticals's investor presentation, Jun 18, 2024

  1. Slide 1: Day One Biopharmaceuticals: Targeted Therapies for People of All Ages

    Exhibit 99.2 Day One Biopharmaceuticals Targeted Therapies for People of All Ages June 2024 1

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Cancer Therapies for People of All Ages

    Cancer Therapies for People of All Ages Our Approach • Develop medicines for genomically-defined cancers • Establish first-in-class position through rapid registration pathways • Expand to adolescent and adult populations in parallel and pursue those opportunities with the same commitment we do for

  4. Slide 4: Our Pipeline

    Our Pipeline Phase 3/ Recent & Anticipated Product Candidate Therapeutic Area Preclinical Phase 1 Phase 2 Approved Registrational Milestones BRAF-altered FDA approval 2 FIREFLY-1 (pivotal Phase 2) Tovorafenib April 2024 Relapsed pLGG Type II RAF Inhibitor OJEMDA brand name Frontline RAF- 1 First pat

  5. Slide 5: OJEMDA (tovorafenib) Relapsed or Refractory BRAF-altered pLGG

    TM OJEMDA (tovorafenib) Relapsed or Refractory BRAF-altered pLGG 5

  6. Slide 6: OJEMDA Now Approved In The U.S.

    OJEMDA Now Approved In The U.S. OJEMDA is the first and only FDA Approved therapy for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation * 6 This indication is approved under accel

  7. Slide 7: pLGG Impact On Patients' Lives

    pLGG Impact On Patients’ Lives Lily was diagnosed with an operable brain tumor at 5 months of age 7 Lily, lives with pLGG.

  8. Slide 8: Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children

    Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children A Serious and Life-Threatening Disease pLGGs are chronic and • For the majority of pLGG patients in the relapsed setting, there is no standard of care and no approved therapies relentless, with patients * • Up to 75% of pLGG

  9. Slide 9: Conventional Treatments Can Be Disruptive To Childhood

    Conventional Treatments Can Be Disruptive To Childhood And Can Have Significant Long-Term Consequences Surgery Chemotherapy Radiation • Significant recovery times • Requirement for indwelling • Risk of secondary malignancy catheter and weekly infusions • Risks of complications • Risk of malignant tr

  10. Slide 10: Overview U.S. Prescribing Information For OJEMDA

    TM Overview U.S. Prescribing Information For OJEMDA (tovorafenib) Available in tablet formulation and pediatric-friendly powder for oral suspension INDICATION OJEMDA is indicated for the treatment of pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma

  11. Slide 11: Efficacy Summary From OJEMDA Prescribing Information

    TM Efficacy Summary From OJEMDA (tovorafenib) Prescribing Information Overall response rate (RAPNO-LGG) in RAPNO-LGG 76 evaluable patients 51% Response (IRC) n n (%) 95% CI ORR, n (%) 76 39 (51) 40-63 BRAF fusion or rearrangement 64 33 (52) 39-64 BRAF V600 mutation 12 6 (50) 21-79 Prior MAPKi use 45

  12. Slide 12: Safety Summary From OJEMDA Prescribing Information

    TM Safety Summary From OJEMDA (tovorafenib) Prescribing Information Warnings and Precautions TEAEs (≥ 30% of patients [n=137]) Preferred Term, n (%) Any Grade Grade ≥3 • Hemorrhage Any AE 137 (100) 86 (63) Hair color changes 104 (76) 0 • Skin toxicity, including photosensitivity Anemia 81 (59) 15 (1

  13. Slide 13: Estimated BRAF-Altered pLGG Patient Population In The U.S.

    Estimated BRAF-Altered pLGG Patient Population In The U.S. ~26,000 Prevalence of Systemically- ~2,000-3,000 Treated Patients 1-5 ~1,100 Under 25 Recurrent/Progressive Total Addressable Incidence of Patient Population Treatment- 6 per Year at Steady Eligible * State Frontline 4,5 Patients 7-14 Up to

  14. Slide 14: What Physicians & Caregivers Are Looking For In A Therapy

    What Physicians & Caregivers Are Looking For In A Therapy What HCP’s are Seeking What Caregivers are Seeking Effective in stopping or shrinking tumors Live as normal of a childhood as possible Manageable safety profile Minimal impact from the disease Minimal disruption to child’s life Minimal disrup

  15. Slide 15: Product Profile Aligns With What Physicians Are Looking For

    Product Profile Aligns With What Physicians Are Looking For In A Therapy Meaningful tumor stabilization or shrinkage may be possible with OJEMDA. In the clinical trial: Efficacy • 51% of children experienced tumor shrinkage by at least 25% • 82% of children saw their tumors shrink or remain stable G

  16. Slide 16: Comprehensive Approach For A Successful Launch

    Comprehensive Approach For A Successful Launch Physicians Payers Patients & Families TM Objective: Establish OJEMDA as Objective: Provide a positive & Objective: Rapidly establish st 1 choice in relapsed / refractory supportive experience when coverage BRAF-altered pLGG patients initiating therapy M

  17. Slide 17: Targeted Launch With Highly Experienced Field Team

    Targeted Launch With Highly Experienced Field Team Targeting ~200 centers where 90% Deep oncology experience with of pLGG patients receive treatment relationships at top-tier accounts Average experience: 18 Account 13 years of oncology Managers fully-dedicated 4 years of rare disease to OJEMDA 2 yea

  18. Slide 18: Patient Support Program Supporting Access

    Patient Support Program Supporting Access DEDICATED PATIENT NAVIGATOR COPAY CARD PHONE & VIDEO PROGRAM CONSULTATIONS COVERAGE PATIENT DELAY ASSISTANCE PROGRAM PROGRAM COVERAGE INTERRUPTION SUPPORT 18

  19. Slide 19: FIREFLY-2 / LOGGIC Pivotal Phase 3 Trial in Frontline pLGG

    FIREFLY-2 / LOGGIC Pivotal Phase 3 Trial of Tovorafenib in Frontline pLGG 19

  20. Slide 20: FIREFLY-2/LOGGIC Pivotal Phase Trial Of Tovorafenib In Frontline pLGG

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib In Frontline pLGG Trial Design Endpoints • Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib • Primary endpoint: ORR based on RAPNO-LGG criteria, assessed by vs SoC chemotherapy blinded independent central review ‒ The O

  21. Slide 21: FIRELIGHT-1 Tovorafenib Combination with Pimasertib

    FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib as a Combination with Pimasertib 21

  22. Slide 22: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor

    Pimasertib: Investigational Allosteric MEK1/2 Inhibitor With Demonstrated Activity In MAPK-Driven Solid Tumors • Pimasertib is an investigational orally-bioavailable, selective, non- competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 • Extensive non-clinical and clinical devel

  23. Slide 23: Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib

    Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib May Unlock Potential Synergy For Adult Solid Tumors BRAF KRAS or NRAS non-V600 mutant mutant MEK RAF/ PI3K/m PI3K/m MEK/ERK TOR TOR ERK Proliferation, survival Proliferation, survival Type II RAFi + MEKI Type II RAFi + MEKI A Type II R

  24. Slide 24: Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1)

    Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1) 1 Trial Design Endpoints 2 • Combination dose escalation, global phase 1b/2 trial • Phase 1b: PK, PD and Safety, MTD/RP2D • Phase 1b, BOIN (adaptive), n = 10/cohort (approximately) • Phase 2: Efficacy (ORR, DOR) • Phase 2, Simon 2-st

  25. Slide 25: DAY301 PTK7 Targeted Antibody Drug Conjugate (ADC)

    DAY301 PTK7 Targeted Antibody Drug Conjugate (ADC) 25

  26. Slide 26: DAY301: Next Generation ADC Targeting PTK7

    DAY301: Next Generation ADC Targeting PTK7 Substantial Development and PTK7: Clinically-Validated ADC DAY301: Potential First-in- Commercial Opportunities for Target Class Asset DAY301 Novel ADC highly active in Anti-tumor activity of anti-PTK7 High PTK7 expression in ADC demonstrated in Phase 1b pr

  27. Slide 27: PTK7: A Clinically-Validated ADC Target

    PTK7: A Clinically-Validated ADC Target Potential opportunity for a next-generation PTK7 ADC with improved therapeutic index 1 • Clinical results for cofetuzumab pelidotin demonstrated proof of concept for PTK7-targeted ADCs • Cofetuzumab pelidotin activity seen in multiple tumor types: • Ovarian (P

  28. Slide 28: DAY301: Potential First-In-Class Asset

    DAY301: Potential First-In-Class Asset DAY301 has been designed to maximize therapeutic index and overcome limitations of prior programs • Tumor regression at tolerable doses seen in multiple preclinical models • Higher HNSTD in cyno toxicology studies; payload with known safety profile DAY301 • Hig

  29. Slide 29: DAY301: First-in-Class Potential

    DAY301: First-in-Class Potential Improved tumor regression activity demonstrated for DAY301 vs. benchmarks in multiple preclinical models PDX 362797 SCLC PDX 362310 TNBC PDX LD1-200615 HNSCC H-score 210 H-score 255 H-score 120 2,400 4,000 3,000 2,000 3,000 1,600 2,000 1,200 2,000 800 1,000 1,000 400

  30. Slide 30: DAY301: Encouraging Development And Commercial Opportunities

    DAY301: Encouraging Development And Commercial Opportunities PTK7 U.S. Patient Population ORR at Median OS at Indication Expression (>1+) Cases/deaths Relapse Relapse 2 3 7 7 Endometrial 100% 67,880/13,250 39% 9 months 1 3 4 4 Esophageal SCC 76% 22,370/16,130 5% 3 months 2 3 14 15 Gastric 35% 26,890

  31. Slide 31: DAY301-001: Initial Phase 1/2a Clinical Trial Design

    DAY301-001: Initial Phase 1/2a Clinical Trial Design Key Design Elements Adult & Pediatric Development • BOIN design for efficiency of dose escalation • Potential adult indications include platinum resistant ovarian cancer, squamous NSCLC, esophageal SCC, HNSCC, endometrial, and/or SCLC • Backfill a

  32. Slide 32: Summary

    Summary 32

  33. Slide 33: Financial Summary: DAWN

    Financial Summary: DAWN Cash, cash equivalents and short-term investments PRV sale in May 2024: $108.0 million ~87.4 million shares of common stock as of March 31, 2024: $317.9 million (no debt) in gross proceeds outstanding as of May 1, 2024 Three Months Ended Three Months Ended $ Millions 3/31/24

  34. Slide 34: Priorities as a Commercial-Stage Company

    Priorities as a Commercial-Stage Company TM Launch OJEMDA (tovorafenib) Advance Portfolio Expand Pipeline • Expand awareness amongst • FIREFLY-2: Study tovorafenib as a • Grow Day One into a leading, physicians and establish broad frontline therapy for treatment- biopharmaceutical company that is co

  35. Slide 35: Appendix

    Appendix 35

  36. Slide 36: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations

    Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations MAPK pathway RAS-independent activation of the MAPK pathway Tovorafenib is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both RAS monomeric and dimeric RAF kinase • Activity in tum

  37. Slide 37: Pivotal Phase Trial Of Monotherapy Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1)

    Pivotal Phase 2 Trial Of Monotherapy Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1) Trial Design Endpoints (Pivotal Arm 1) 1 • Three arm, open-label, global registrational phase 2 trial • Primary endpoint: ORR based on RANO-HGG , assessed by blinded independent central review • Pivotal Arm

  38. Slide 38: Data from Pivotal Phase FIREFLY-1 Trial

    Data from Pivotal Phase 2 FIREFLY-1 Trial June 5, 2023 data cutoff 38

  39. Slide 39: FIREFLY-1 Baseline Patient Characteristics

    FIREFLY-1 Baseline Patient Characteristics Characteristic Arm 1 (n=77) Location (n=77) Deep midline structures Optic pathway Median age, years (range) 8 (2-21) 12% 51% Sex, n (%) Other Male 40 (52) † 16% Female 37 (48) Cerebral hemisphere 8% Race, n (%) Cerebellum Brain stem White 41 (53) 6% 8% Asia

  40. Slide 40: Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG

    Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG RAPNO-LGG RAPNO-LGG RANO-LGG RANO-HGG Response (IRC) n=76 N=76 N=69 ORR,* n (%) 39 (51) 40 (53) 46 (67) 95% CI 40-63 41-64 54-78 CBR,* n (%) 62 (82) 63 (83) 64 (93) SD of any length of time 43 (57) 46 (61) 54 (78) SD ≥12 months RAN

  41. Slide 41: Duration Of Tovorafenib Therapy For Patients With RAPNO-LGG Evaluable Lesions

    Duration Of Tovorafenib Therapy For All Patients With RAPNO-LGG Evaluable Lesions 5.3 Median time to response Months Median duration of 13.8 treatment Months Overall treatment duration (months) 41 June 5, 2023 data cutoff. Patients

  42. Slide 42: Duration Of Tovorafenib Therapy For Patients With RANO-HGG Evaluable Lesions

    Duration Of Tovorafenib Therapy For All Patients With RANO-HGG Evaluable Lesions 3.0 Median time to response Months Median duration of 16.6 treatment Months Overall treatment duration (months) 42 June 5, 2023 data cutoff. Patients

  43. Slide 43: Duration Of Tovorafenib Therapy For Patients With RANO-LGG Evaluable Lesions

    Duration Of Tovorafenib Therapy For All Patients With RANO-LGG Evaluable Lesions 5.5 Median time to response Months Median duration of 14.4 treatment Months Overall treatment duration (months) 43 June 5, 2023 data cutoff. Patients

  44. Slide 44: Tumor Response To Tovorafenib Across Three Assessment Criteria

    Tumor Response To Tovorafenib Across Three Assessment Criteria Were Consistent Across BRAF Fusion And Mutation Patients, and Patients With Prior MAPK Treatment 2 3,4 1 RAPNO-LGG RANO-LGG RANO-HGG Response (IRC) n n n ORR,* n (%) 76 39 (51) 76 40 (53) 69 46 (67) BRAF fusion 64 33 (52) 64 33 (52) 59 4

  45. Slide 45: Tovorafenib Safety Data (n=137)

    Tovorafenib Safety Data (n=137) TEAEs TRAEs Preferred Term, n (%) Any Grade Grade ≥3 Any Grade Grade ≥3 Any AE 137 (100) 86 (63) 134 (98) 58 (42) Hair color changes 104 (76) 0 104 (76) 0 • The most common reasons Anemia 81 (59) 15 (11) 67 (49) 14 (10) Elevated CPK 80 (58) 16 (12) 77 (56) 16 (12) for

Day One Biopharmaceuticals — Investor Presentation (June 2024) on 6ix